Ascendis Pharma A/S: financial analysis
Ratios worked out from 10 fiscal years of Ascendis Pharma A/S's statements, compared with 665 companies in Biotechnology.
Ascendis Pharma A/S scorecard#
Passes 8 of the 12 checks that could be worked out: strongest in growth (5 of 6), weakest in profitability (2 of 4). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth5 of 6
- ✓Revenue grew in the newest year106.4%Revenue up 106.4% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years147.2%147.2% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median147.2%147.2% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-4.24 vs -7.07Diluted EPS -4.24 in fiscal 2025 against -7.07 the year before (report's currency).
- ✓Net income higher than five years earlier-$257 M-$257 M in fiscal 2025 against -$478 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability2 of 4
- ✗Profitable in the newest year-$257 MNet income -$257 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-18.9%-18.9% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-18.9%-18.9% in fiscal 2025 against -1097.8% in 2022.
Financial health1 of 2
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $271 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Strengths
- Revenue has grown 5 years in a row.
- More cash than debt: net cash of $271 million.
Worth a look
- Net loss of $257 million, the 11th loss-making year in a row.
- Shareholders' equity is negative: -$191 million.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashyes
- Return on assets roseyes
- Cash from operations exceeds profityes
- Long-term debt fell against assetsyes
- Current ratio rosenot on file
- No new shares issuedno
- Gross margin roseno
- Asset turnover roseyes
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 86.8% | 87.8% | 83.4% | 76.3% | 54.7% | 74.8% | 65% | |
| Operating margin | -18.9% | -76.7% | -170.8% | — | — | -60.5% | 61% | |
| Net margin | -31.7% | -104.0% | -180.5% | — | — | -68.9% | 57% | |
| Return on equity | — | — | — | -95.6% | -44.7% | -61.0% | — | |
| Return on assets | -18.7% | -38.3% | -50.2% | -51.3% | -37.3% | -44.4% | 77% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 106.4% | 36.5% | 436.2% | 485.1% | 15.9% | 15.8% | 84% | |
| Revenue growth, 3 years a year | 147.2% | 249.9% | 231.3% | 53.2% | -9.7% | 12.9% | 96% | |
| Revenue growth, 5 years a year | 152.4% | 92.3% | 87.4% | 99.1% | 12.5% | 15.4% | 99% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Debt to equity | — | — | — | 1.47× | 0.11× | 0.26× | — | |
| Net debt | $-271 M | $-202 M | $-187 M | $-61 M | $-394 M | $-16 M | 91% | |
| Interest cover | — | — | — | — | — | -22.77× | — | |
| Current ratio | — | — | — | — | — | 4.39× | — | |
| Equity share of assets | -12.5% | -9.0% | -17.7% | 24.2% | 81.5% | 64.7% | 15% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | — | — | $-508 M | $-536 M | $-522 M | $-40 M | — | |
| Free cash flow margin | — | — | -176.1% | -996.9% | — | -61.5% | — | |
| Capital spending share of revenue | — | — | 0.9% | 28.3% | 304.9% | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.59× | 0.37× | 0.28× | 0.04× | 0.01× | 0.26× | 77% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Debt to equity
- Total debt divided by shareholders' equity. Not given when equity is negative.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).